Other formats:
BibTeX
LaTeX
RIS
@misc{2365862,
author = {Žáčková, Daniela},
booktitle = {29th meeting of the European Investigators on CML (EI-CML)},
keywords = {chronic myeloid leukemia; TFR; HALF; CLINICAL TRIAL},
language = {eng},
title = {Why are not all eligible CML patients willing to attempt TFR? A nationwide analysis related to the TKI stopping trail HALF},
url = {https://www.infocongressi.com/congressi-medici-2023/29th-meeting-of-the-european-investigators-on-chronic-myeloid-leukemia-ei-cml#gsc.tab=0},
year = {2023}
}
TY - SLIDE
ID - 2365862
AU - Žáčková, Daniela
PY - 2023
TI - Why are not all eligible CML patients willing to attempt TFR? A nationwide analysis related to the TKI stopping trail HALF
KW - chronic myeloid leukemia
KW - TFR
KW - HALF
KW - CLINICAL TRIAL
UR - https://www.infocongressi.com/congressi-medici-2023/29th-meeting-of-the-european-investigators-on-chronic-myeloid-leukemia-ei-cml#gsc.tab=0
N2 - A prospective phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitor withdrawal after prior two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission The HALF clinical trial is designed as a prospective, multicenter, nonrandomized, open-label phase II study to assess the efficacy and safety of tyrosine kinase inhibitor withdrawal after a prior two-step dose reduction in patients with chronic myeloid leukemia in deep remission. The clinical evaluation of HALF could contribute to the formulation of a new disease management strategy for patients achieving sustained remission with the potential for wider benefits not only for the patients themselves, but also for the healthcare system.
ER -
ŽÁČKOVÁ, Daniela. Why are not all eligible CML patients willing to attempt TFR? A nationwide analysis related to the TKI stopping trail HALF. In \textit{29th meeting of the European Investigators on CML (EI-CML)}. 2023.
|
